Matteo Tebaldi
pubblicato il
22/04/2013 14:30,
ultima modifica
18/05/2021 14:05
26/04/1980 00:00
DIRIGENTE MEDICO CARDIOLOGIA
Azienda Usl di Ferrara
Incarico di Natura Professionale
Azienda Usl di Ferrara in comando c/o Azienda Ospedaliero Universitaria di Ferrara
0532-239889
0532-236593
tblmtt@unife.it
Laurea in Medicina e Chirurgia
Specializzazione in Cardiologia
Dal 01/10/2011 al 30/09/2013 Assegnista di Ricerca c/o L' Università degli studi di Ferrara. Dal 27/10/2011 al 30/09/2013 Libero Professionista c/o la Cardiologia dell' Azienda Ospedaliero-Universitaria di Ferrara. Dal 15/07/2013 al 01/10/2013 Assunzione a tempo indeterminato come Dirigente Medico di Cardiologia c/o la Cardiologia dell' ULSS 8 Asolo –ospedale S. giacomo Castelfranco Veneto Dal 02/11/2013 assunzione a tempo indeterminato come Dirigente Medico di Cardiologia c/o USL di Ferrara in Comando presso Azienda Ospedaliero Universitaria di Ferrara.
Inglese, Francese
Intermedio
Intermedio
Tecniche di immaging coronarico (IVUS, OCT) Tecniche di valutazione funzionale delle stenosi coronariche (FFR)
Pubblicazioni: 1. Tumscitz C, Pirani L, Tebaldi M, Campo G, Biscaglia S. Seven french radialartery access for PCI: A prospective single-center experience. Int J Cardiol.2014 Aug 2. 2. 2: Vranckx P, Leonardi S, Tebaldi M, Biscaglia S, Parrinello G, Rao SV, Mehran R,Valgimigli M. Prospective validation of the Bleeding Academic Research Consortiumclassification in the all-comer prodigy trial. Eur Heart J. 2014 Apr 21. 3. Sciahbasi A, Calabrò P, Sarandrea A, Rigattieri S, Tomassini F, Sardella G,Zavalloni D, Cortese B, Limbruno U, Tebaldi M, Gagnor A, Rubartelli P, Zingarelli A, Valgimigli M. Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures:rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX - RAdiation Dose study (RAD-MATRIX). Cardiovasc Revasc Med. 2014 Jun;15(4):209-13. 4. 4: Valgimigli M, Campo G, Penzo C, Tebaldi M, Biscaglia S, Ferrari R; RADAR investigators. Transradial coronary catheterization and intervention across the whole spectrum of Allen test results. J Am Coll Cardiol. 2014 May13;63(18):1833-41. 5. Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. 6. Valgimigli M, Patialiakas A, Thury A, Colangelo S, Campo G, Tebaldi M, Ungi I,Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study. Am Heart J. 2013 Nov;166(5):831-8. 7. Campo G, Tebaldi M, Vranckx P, Biscaglia S, Tumscitz C, Ferrari R, Valgimigli M. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). J Am Coll Cardiol. 2014 Feb 18;63(6):506-12. 8. Campo G, Pavasini R, Pollina A, Tebaldi M, Ferrari R. On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention. Thorax. 2014 Jan;69(1):80-1. 9. Campo G, Pavasini R, Pollina A, Tebaldi M, Ferrari R. Coagulation factors and recurrence of ischemic and bleeding adverse events in patients with acute coronary syndromes. Thromb Res. 2013 Aug;132(2):151-7. 10. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R, PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).Eur Heart J. 2013 Mar;34(12):909-19. 11. Biscaglia S, Tebaldi M, Vranckx P, Campo G, Valgimigli M. Effects of pre-hospital Clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention.Biscaglia S, Tebaldi M, Vranckx P, Campo G, Valgimigli M.J Thromb Haemost. 2012 Oct 31. doi: 10.1111/jth.12049. 12. Campo G, Napoli N, Serenelli C, Tebaldi M, Ferrari R. Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction. Int J Cardiol. 2012 Oct 18. doi:pii: S0167-5273(12)01321-6. 13. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gómez-Hospital JA, Baz JA, Martin-Yuste V, van Geuns RJ, Alfonso F, Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.Lancet. 2012 Oct 27;380(9852):1482-90. 14. Campo G, Pavasini R, Pollina A, Fileti L, Marchesini J, Tebaldi M, Ferrari R. Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients? Blood Coagul Fibrinolysis. 2012 Dec;23(8):680-7 15. Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R; FABOLUS PRO Investigators Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.JACC Cardiovasc Interv. 2012 Mar;5(3):268-77. 16. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fucà G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012 April 24;125(16):2015-26 17. Campo G, Marchesini J, Fileti L, Tebaldi M, Ferrari R. Medical and Interventional Management of Patients with Severe Thrombocytopenia undergoing Percutaneous Coronary Intervention J Thromb Haemost. 2011 Nov 12. doi 10.1111/j.1538-7836.2011.04563 18. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011 Jun 21;57(25):2474-83. PubMed PMID: 21679849. 19. Campo G, Miccoli M, Tebaldi M, Marchesini J, Fileti L, Monti M, Valgimigli M, Ferrari R. Genetic determinants of on-clopidogrel high platelet reactivity. Platelets. 2011 May 31. [Epub ahead of print] PubMed PMID: 21627411. 20. Valgimigli M, Campo G, Percoco G, Monti M, Ferrari F, Tumscitz C, Zuffi A, Colombo F, Kubbajeh M, Cavazza C, Cangiano E, Tebaldi M, Minarelli M, Arcozzi C, Scalone A, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). Am Heart J. 2010 Nov;160(5):804-11. PubMed PMID: 21095265. 21. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19. Review. PubMed PMID: 20670206 22. Valgimigli M, Campo G, Tebaldi M, Monti M, Gambetti S, Scalone A, Parrinello G, Ferrari R; Fabolus Synchro (facilitation through abciximab by dropping infusion Line in patients undergoing coronary stenting. Synergy with clopidogrel at high loading dose regimen) Investigators. Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting. J Thromb Haemost. 2010 Sep;8(9):1903-11. doi: 10.1111/j.1538-7836.2010.03972.x. PubMed PMID: 20586923. 23. Campo G, Fileti L, Valgimigli M, Tebaldi M, Cangiano E, Cavazza C, Marchesini J, Ferrari R. Poor response to clopidogrel: current and future options for its management. J Thromb Thrombolysis. 2010 Oct;30(3):319-31. Review. PubMed PMID: 20157839. 24. Tebaldi M, Arcozzi C, Campo G, Percoco G, Ferrari R, Valgimigli M; STRATEGY Investigators. The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2009 Nov 10;54(20):1900-1. PubMed PMID: 19892243. 25. Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AW, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49. Epub 2009 Sep 14. Review. PubMed PMID: 19755402. 26. Campo G, Valgimigli M, Frangione A, Tebaldi M, Ferrari R. Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. J Thromb Haemost. 2008 Oct;6(10):1824-6. Epub 2008 Jul 28. PubMed PMID: 18665918. 27. Valgimigli M, Campo G, Tebaldi M, Carletti R, Arcozzi C, Ferrari R, Percoco G. Abciximab: a reappraisal of its use in coronary care. Biologics. 2008 Mar;2(1):29-39. PubMed PMID: 19707425; PubMed Central PMCID: PMC2727773. 28. Campo G, Valgimigli M, Gemmati D, Percoco G, Catozzi L, Frangione A, Federici F, Ferrari F, Tebaldi M, Luccarelli S, Parrinello G, Ferrari R. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol. 2007 Sep 18;50(12):1132-7. Epub 2007 Sep 4. PubMed PMID: 17868803. 29. Autore del Capitolo “ Fractional flow reserve” pubblicato nel libro “ Diagnostica coronarica e cardiaca avanzata” di Massimo Margheri; Edizione Minerva Medica; 2011.
